secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-09-20T23:59:59+00:00
Accession:  0001104659-22-101298
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics terminates PERFECT study of Tyvaso for PH associated with COPD
--------------------------------------------------------------------------------

- DSMC recommended termination after routine safety and efficacy analysis.
- Study evaluated Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension with COPD.
- Company will review available data and share results with the scientific community.
- Tyvaso is already approved for PAH and PH-ILD; termination affects a potential label expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922101298/0001104659-22-101298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922101298/tm2226246d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-101298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer